The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2106-2108 May 17, 2007 Number 20
NextNext

Inhaled Insulin for Diabetes Mellitus

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by McMahon, G. T.
-PubMed Citation
To the Editor: An important uncertainty about treatment with inhaled insulin is the potentially increased risk of lung cancer. In their Clinical Therapeutics article on inhaled insulin for diabetes mellitus, McMahon and Arky (Feb. 1 issue)1 report that short-term studies in animals have not shown a substantial effect on cell-proliferation indexes in the alveolar or bronchiolar areas of the lung. This is not quite correct. One of the short-term studies reports an increased rate of mitosis induced by inhaled insulin in rats.2

Presumably in response to this finding, Pfizer, the manufacturer of a dry-powder formulation of human insulin, proposed to . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.